Prof. Dr. Erdinç Nayır

Unlu A, Nayir E, Dogukan Kalenderoglu M, Kirca O, Ozdogan M. Curcumin (Turmeric) and cancer. J BUON. 2016 Sept-Oct;21(5):1050-1060. PMID: 27837604.

Unlu A, Nayir E, Kirca O, Ay H, Ozdogan M. Ginseng and cancer. J BUON. 2016 Nov-Dec;21(6):1383-1387. PMID: 28039696.

Unlu A, Nayir E, Kirca O, Ozdogan M. Ganoderma Lucidum (Reishi Mushroom) and cancer. J BUON. 2016 Jul-Aug;21(4):792-798. PMID: 27685898.

Vatansever M, Bozkurt FM, Dinç E, Yılmaz EB, Nayir E, Sarı AA, Yıldırım Ö, Kara T. Orbital Metastasis of Multiple Myeloma: Case Report. Turk J Ophthalmol. 2016 Jun;46(3):148-150. doi: 10.4274/tjo.73645. Epub 2016 Jun 6. PMID: 27800278.

Almuradova E, Basoglu T, Nayir E, Bayram E, Paydas S, Gokmen I, Karakaya S, Oksuzoglu B, Erdem D, Sakin A, Atcı M, Belen Gulbagcı B, Hacibekiroglu I, Onder AH, Karaarslan S, Karakurt Eryılmaz M, Korkmaz M, Yazıcı O, Sutcuoglu O, Akagunduz B, Arak H, Sakalar T, Aydin D, Iriagac Y, Alan O, Midik M, Cetin D, Kip AD, Turhal S, Kacan T, Koseci T. Real-life experience of patients with sarcomatoid renal cell carcinoma: a multicenter retrospective study. Neoplasma. 2023 Feb;70(1):158-165. doi: 10.4149/neo_2022_221004N984. Epub 2023 Jan 9. PMID: 36620878.

Koseci T, Haksoyler V, Olgun P, Ata S, Nayir E, Duman BB, Cil T. Prognostic Importance of Inflammatory Indexes in Patients Treated by Pazopanib for Soft Tissue Sarcoma. Clin Lab. 2022 Feb 1;68(2). doi: 10.7754/Clin.Lab.2021.210431. PMID: 35142203.

Koksal B, Yildirim HC, Guven DC, Kose F, Koymen G, Ozdemir O, Ozberk U, Algin E, Guliyev M, Demirci NS, Alan O, Baklaci A, Demir B, Topkaya O, Uskent N, Yucel KB, Akdogan O, Koylu B, Selcukbiricik F, Bilgetekin I, Helvaci K, Unal A, Semiz HS, Sakalar T, Sever N, Cicek CM, Dogu GG, Biter S, Bayram E, Yildiz C, Demir H, Bayrakci I, Erdogan B, Kalender ME, Guzel HG, Ozturk B, Karabuga B, Ates O, Cetin EB, Sahbazlar M, Inal A, Sunar V, Basal FB, Asik E, Yildirim A, Oksuz NE, Urun Y, Nayir E, Turker S, On S, Aytac A, Menekse S, Temi YB, Uygun K, Sahin E, Keskinkilic M, Arik Z. Outcomes of First-Line PARP Inhibitor Therapy in Ovarian Cancer: A Multicenter Retrospective Analysis. J Clin Med. 2026 Feb 22;15(4):1657. doi: 10.3390/jcm15041657. PMID: 41753346.

Efil SC, Bilgin B, Bilgetekin I, Helvaci K, Sakalar T, Nayir E, Erdem Palaz FE, Guren AK, Biter S, Sahin TK, Bayram E, Kertmen N, Arslan AM, Asık E, Akdogan O, Alan O, Fidan E, Yazici O, Sahin E, Kut E, Mordag Cicek C, Turker S, Kolkiran N, Gokoz Dogu G, Sahbazlar M, Batu A, Kilictas B, Yilmaz M, Oksuz NE, Artac M, Akbas S, Algin E, Urun Y, Sendur MAN, Yalcin B. Prognostic impact of hand-foot skin reaction in regorafenib-treated adult-type diffuse gliomas: A multicenter Turkish Oncology Group study. Sci Rep. 2025 Oct 16;15(1):36175. doi: 10.1038/s41598-025-19899-3. PMID: 41102268.

Guven DC, Aykan MB, Muglu H, Bayram E, Helvaci K, Dursun B, Celayir M, Chelebiyev E, Nayir E, Erman M, Sezer A, Urun Y, Demirci U, Er O, Disel U, Bilici A, Arslan C, Karadurmus N, Kilickap S. The efficacy of immunotherapy and chemoimmunotherapy in patients with advanced rare tumors: A Turkish oncology group (TOG) study. Cancer Med. 2024 Jan;13(1):e6869. doi: 10.1002/cam4.6869. Epub 2023 Dec 22. PMID: 38140782.

Karacin C, Oksuzoglu B, Demirci A, Keskinkılıç M, Baytemür NK, Yılmaz F, Selvi O, Erdem D, Avşar E, Paksoy N, Demir N, Göksu SS, Türker S, Bayram E, Çelebi A, Yılmaz H, Kuzu ÖF, Kahraman S, Gökmen İ, Sakin A, Alkan A, Nayır E, Uğraklı M, Acar Ö, Ertürk İ, Demir H, Aslan F, Sönmez Ö, Korkmaz T, Celayir ÖM, Karadağ İ, Kayıkçıoğlu E, Şakalar T, Öktem İN, Eren T, Erul E, Mocan EE, Kalkan Z, Yıldırım N, Ergün Y, Akagündüz B, Karakaya S, Kut E, Teker F, Demirel BÇ, Karaboyun K, Almuradova E, Ünal OÜ, Oyman A, Işık D, Okutur K, Öztosun B, Gülbağcı BB, Kalender ME, Şahin E, Seyyar M, Özdemir Ö, Selçukbiricik F, Kanıtez M, Dede İ, Gümüş M, Gökmen E, Yaren A, Menekşe S, Ebinç S, Aksoy S, İmamoğlu Gİ, Altınbaş M, Çetin B, Uluç BO, Er Ö, Karadurmuş N, Erdoğan AP, Artaç M, Tanrıverdi Ö, Çiçin İ, Şendur MAN, Oktay E, Bayoğlu İV, Paydaş S, Aydıner A, Salim DK, Geredeli Ç, Yavuzşen T, Doğan M, Hacıbekiroğlu İ. Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy. BMC Cancer. 2023 Feb 10;23(1):136. doi: 10.1186/s12885-023-10609-8. PMID: 36765293.

Karacin C, Oksuzoglu B, Demirci A, Keskinkılıç M, Baytemür NK, Yılmaz F, Selvi O, Erdem D, Avşar E, Paksoy N, Demir N, Göksu SS, Türker S, Bayram E, Çelebi A, Yılmaz H, Kuzu ÖF, Kahraman S, Gökmen İ, Sakin A, Alkan A, Nayır E, Uğraklı M, Acar Ö, Ertürk İ, Demir H, Aslan F, Sönmez Ö, Korkmaz T, Celayir ÖM, Karadağ İ, Kayıkçıoğlu E, Şakalar T, Öktem İN, Eren T, Erul E, Mocan EE, Kalkan Z, Yıldırım N, Ergün Y, Akagündüz B, Karakaya S, Kut E, Teker F, Demirel BÇ, Karaboyun K, Almuradova E, Ünal OÜ, Oyman A, Işık D, Okutur K, Öztosun B, Gülbağcı BB, Kalender ME, Şahin E, Seyyar M, Özdemir Ö, Selçukbiricik F, Kanıtez M, Dede İ, Gümüş M, Gökmen E, Yaren A, Menekşe S, Ebinç S, Aksoy S, İmamoğlu Gİ, Altınbaş M, Çetin B, Uluç BO, Er Ö, Karadurmuş N, Erdoğan AP, Artaç M, Tanrıverdi Ö, Çiçin İ, Şendur MAN, Oktay E, Bayoğlu İV, Paydaş S, Aydıner A, Salim DK, Geredeli Ç, Yavuzşen T, Doğan M, Hacıbekiroğlu İ. Correction: Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy. BMC Cancer. 2023 Feb 27;23(1):192. doi: 10.1186/s12885-023-10662-3. PMID: 36849943.

Karadurmus N, Paydas S, Esin E, Surmeli ZG, Yildiz B, Erturk I, Nayir E, Dogan M, Sumbul AT, Barista I, Gurkan E, Ocal R, Ferhanoglu B, Ozgur G, Karakas Y, Lacin S, Ozaydin S, Petekkaya HI, Uskent N. Effectiveness of bendamustine in relapsed or refractory lymphoma cases: a Turkish Oncology Group study. Arch Med Sci. 2019 Feb 18;17(4):920-927. doi: 10.5114/aoms.2019.83000. eCollection 2021. PMID: 34336021.

Özdemir Ö, Zengel B, Yildiz Y, Uluç BO, Cabuk D, Ozden E, Salim DK, Paydas S, Demir A, Diker O, Pilanci KN, Sönmez ÖU, Vatansever S, Dogan I, Gulmez A, Cakar B, Gursoy P, Yildirim ME, Ayhan M, Karadurmus N, Aykan MB, Cevik GT, Sakalar T, Hacibekiroglu I, Gülbagci BB, Dincer M, Garbioglu DB, Kemal Y, Nayir E, Taskaynatan H, Yilmaz M, Avci O, Sari M, Coban E, Atci MM, Esen SA, Telli TA, Karatas F, Inal A, Demir H, Kalkan NO, Yilmaz C, Tasli F, Alacacioglu A. The effectiveness and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early-stage human epidermal growth factor receptor 2-positive breast cancer: Turkish Oncology Group study. Anticancer Drugs. 2022 Aug 1;33(7):663-670. doi: 10.1097/CAD.0000000000001310. Epub 2022 Jun 20. PMID: 35703239.

Erol C, Sendur MAN, Bilgetekin I, Garbioglu DB, Hamdard J, Akbas S, Hizal M, Arslan C, Sevinc A, Kucukarda A, Erdem D, Kahraman S, Cakir E, Demirkiran A, On S, Dogan I, Erdogan AP, Koca S, Kubilay P, Eren OO, Cilbir E, Celik E, Araz M, Ozyukseler DT, Yildirim ME, Bahceci A, Taskaynatan H, Oyman A, Deniz GI, Menekse S, Kut E, Gulmez A, Sakin A, Nayir E, Acar R, Sen E, Inal A, Turhal S, Kaya AO, Paydas S, Tastekin D, Hacibekiroglu I, Cincin I, Bilici A, Mandel NM, Dede DS, Akinci MB, Oksuzoglu B, Uncu D, Yalcin B, Artac M. Efficacy and safety of folfiri plus aflibercept in second-line treatment of metastatic colorectal cancer: Real-life data from Turkish oncology group. J Cancer Res Ther. 2022 Dec;18(12 Suppl 2):S347-S353. doi: 10.4103/jcrt.jcrt_1104_21. PMID: 36510987.

Abali H, Celik I, Karaca B, Turna H, Kaytan Saglam E, Akman T, Oztop I, Senol Coskun H, Serdar Turhal N, Sezer A, Nayir E, Arican A, Ozkan M, Sevinc A, Demir G, Budakoglu B, Issikdogan A, Engin H, Kilickap S, Coskun U, Oyan B, Harputluoglu H, Er O, Kavgaci H, Elk Ran T. Cutaneous melanoma in Turkey: analysis of 1157 patients in the Melanoma Turkish Study. J BUON. 2015 Jul-Aug;20(4):1137-41. PMID: 26416068.

Alkan A, Yaşar A, Güç ZG, Gürbüz M, Başoğlu T, Sezgin Göksu S, Buğdaycı Başal F, Türk HM, Özdemir Ö, Yeşil Çınkır H, Güven DC, Kuş T, Türker S, Koral L, Karakaş Y, Ak N, Paydaş S, Karcı E, Demiray AG, Demir A, Alan Ö, Keskin Ö, Nayır E, Tanrıverdi Ö, Yavuzşen T, Yumuk PF, Ateş Ö, Coşkun HŞ, Turhal S, Çay Şenler F. Worse patient-physician relationship is associated with more fear of cancer recurrence (Deimos Study): A study of the Palliative Care Working Committee of the Turkish Oncology Group (TOG). Eur J Cancer Care (Engl). 2020 Nov;29(6):e13296. doi: 10.1111/ecc.13296. Epub 2020 Aug 30. PMID: 32864838.

Yuksel HC, Almuradova E, Buyukahiska O, Yilmaz B, Acar C, Sahin G, Tunbekici S, On S, Akar H, Sahbazlar M, Bayram E, Ergozoglu MA, Tazebay BN, Cabuk D, Kitapli S, Acikgoz Yildiz B, Yildiz S, Cosar R, Akin Telli T, Yilmaz M, Hacibekiroglu I, Sakalar T, Majidova N, Petrovska G, Celebi G, Kalender ME, Rahman M, Akosman C, Danaci Y, Nayir E, Gursoy P, Gokmen E. Ten-year risk of second primary malignancies among chemotherapy-treated early-stage breast cancer survivors: a multicentre cohort study from the Turkish Oncology Group. Front Oncol. 2026 Jul 7;16:1756315. doi: 10.3389/fonc.2026.1756315. eCollection 2026. PMID: 42482752.

Bilir C, Yıldız İ, Bilici A, Ucar M, Berk V, Yıldız Y, Yazıcı O, İmamoğlu Gİ, Karadurmuş N, Pilancı KN, Arpacı E, Tanrıverdi Ö, Karcı E, Temiz S, Nayır E, Oktay E, Dal P, Petekkaya İ, Varım C, Cinemre H. Is Change in Hemoglobin Level a Predictive Biomarker of Tyrosine Kinase Efficacy in Metastatic Renal Cell Carcinoma? A Turkish Oncology Group Study. Cancer Invest. 2017 Apr 21;35(4):248-255. doi: 10.1080/07357907.2017.1292518. Epub 2017 Mar 23. PMID: 28333566.

Demircan NC, Özdemir M, Ballı S, Köse Baytemur N, Helvacı K, Akbaş S, Efil SC, Sümbül AT, Çelebi A, Karakaya S, Kahraman S, Güven DC, Kutlu Y, Işık D, İnal A, Uğurlu İ, Nayır E, Uzun M, Gököz Doğu G, Demirkazık A, Demirci U, Selçukbiricik F, Şendur MAN, Bayoğlu İV, Kılıçkap S, Bilici A, Hacıbekiroğlu İ, Karaoğlu A, Tatlı AM, Yumuk PF. Nutritional Indexes and Their Variations as Predictors of Atezolizumab Plus Chemotherapy Efficacy in Extensive-Stage Small Cell Lung Cancer: A Turkish Oncology Group Study. J Immunother. 2026 Oct 1;49(8):307-313. doi: 10.1097/CJI.0000000000000610. PMID: 42267536.

Degirmencioglu S, Tanriverdi O, Menekse S, Dogan M, Hacıoglu B, Oktay E, Erdem D, Arpaci E, Uluc BO, Turhal S, Yilmaz M, Pilanci KN, Sakin A, Araz M, Cokmert S, Ozdemir O, Sen E, Nayir E. A retrospective analysis on first-line bevacizumab, cetuximab, and panitimumab-containing regimens in patients with RAS-wild metastatic colorectal cancer: A Collaborative Study by Turkish Oncology Group (TOG). J BUON. 2019 Jan-Feb;24(1):136-142. PMID: 30941962.

Köşeci T, Seyyar M, Kıdı MM, Biter S, Eser K, Kefeli U, Nayır E, Duman BB, Mete B, Demirhindi H, Çil T. Prognostic Significance of the Combined Albumin-To-Alkaline Phosphatase Ratio (AAPR) and Haemoglobin-Albumin-Lymphocyte-Platelet (HALP) Score in Patients with Metastatic Renal Cell Carcinoma Treated by Targeted Therapy: A New Prognostic Combined Risk Scoring. J Clin Med. 2025 Mar 5;14(5):1742. doi: 10.3390/jcm14051742. PMID: 40095849.

Nayir E, Tanriverdi O, Karakas Y, Kilickap S, Serdar Turhal N, Avci N, Okutur K, Koca D, Erdem D, Abali H, Yamac D, Bilir C, Kacan T. Tendency of cancer patients and their relatives to use internet for health-related searches: Turkish Oncology Group (TOG) Study. J BUON. 2016 May-Jun;21(3):714-9. PMID: 27569068.

Akça M, Ata A, Nayır E, Erdoğdu S, Arıcan A. Impact of Surgery Type on Quality of Life in Breast Cancer Patients. J Breast Health. 2014 Oct 1;10(4):222-228. doi: 10.5152/tjbh.2014.1919. eCollection 2014 Oct. PMID: 28331675.

Oktay E, Levent M, Gelincik H, Aktaş G, Yumuk F, Koral L, Arpacı E, Keser M, Alkan A, Karci E, Karadurmuş N, Degirmencioglu S, Turan M, Uyeturk U, Cabuk D, Avci N, Toprak O, Ergen A, Urvay S, Bayman E, Petekkaya E, Nayir E, Paydaş S, Yavuzsen T, Senler FC, Yaren A, Barutca S, Şahinler İ, Ozyilkan O, Tanriverdi O. Perspective of Turkish Medicine Students on Cancer, Cancer Treatments, Palliative Care, and Oncologists (ARES Study): a Study of the Palliative Care Working Committee of the Turkish Oncology Group (TOG). J Cancer Educ. 2020 Feb;35(1):69-75. doi: 10.1007/s13187-018-1441-6. PMID: 30446981.

Bilir C, Durak S, Kızılkaya B, Hacıbekiroglu I, Nayır E, Engin H. Efficacy of metronomic vinorelbine in elderly patients with advanced non-small-cell lung cancer and poor performance status. Curr Oncol. 2017 Jun;24(3):e199-e204. doi: 10.3747/co.24.3486. Epub 2017 Jun 27. PMID: 28680287.

Nayir E, Ata A, Arican A. Do medical oncologists and cancer patients care about treatment costs of systemic anticancer therapy? J BUON. 2015 Nov-Dec;20(6):1606-11. PMID: 26854459.

Nayir E, Bakir Koyuncu M, Esin E, Turker I, Tanriverdi O, Uysal M, Er O, Demir A, Tuzel Akman T, Nur Pilanci K, Paydas S, Kocar M, Saip P, Kilickap S, Turhal S, Kacan T. Attitudes of cancer patients after diagnosis: How cancer affects social life? A Turkish Oncology Group study. J BUON. 2017 Jan-Feb;22(1):208-213. PMID: 28365956.

Murat Sedef A, Taner Sumbul FKA, Ayberk Besen A, Hacioglu B, Gunaldi M, Nayir E, Tanriverdi O, Arpaci E, Abali H, Ozyilkan O. Addition of taxanes to combination chemotherapy in distal intestinal gastric cancer is more beneficial than proximal ones: A multicenter retrospective study of Turkish Oncology Group. J BUON. 2019 Mar-Apr;24(2):650-655. PMID: 31128019.

Sezgin O, Altintaş E, Nayir E, Uçbilek E. A pilot study evaluating sequential administration of a PPI-amoxicillin followed by a PPI-metronidazole-tetracycline in Turkey. Helicobacter. 2007 Dec;12(6):629-32. doi: 10.1111/j.1523-5378.2007.00547.x. PMID: 18001405.

Akbay E, Muslu N, Nayir E, Ozhan O, Kiykim A. Serum retinol binding protein 4 level is related with renal functions in Type 2 diabetes. J Endocrinol Invest. 2010 Nov;33(10):725-9. doi: 10.1007/BF03346678. Epub 2010 Apr 30. PMID: 20436266.

Tanriverdi O, Barista I, Paydas S, Nayir E, Karakas Y. Oncologists’ Perspectives on Consolidation Radiation Treatment after Chemotherapy for Lymphomas: A Survey Study by the Lymphoma Working Committee of the Turkish Oncology Group (TOG). Asian Pac J Cancer Prev. 2017 Nov 26;18(11):3149-3155. doi: 10.22034/APJCP.2017.18.11.3149. PMID: 29172293.

Eras N, Nayir E, Arican A, Bahar L, Guler M, Akbas E. TS 1494del6 polymorphism and increased risk of developing breast cancer. Int J Clin Exp Med 2016 ;9(6) :11756-11763

Nayır E, Ata A, Erdoğdu S, Arıcan A. Türkiye’de onkoloji alanındaki klinik araştırmaların durumu. Türk Onkoloji Dergisi 2014;29(4):181-182

Nayır E, Aygün S, Ata A, Arıcan A. Relationship Between IL-18 and Bone Metastasis in Female Breast Cancer Turk J Oncol 2016;31(1):10-14

Unlu A, Nayır E, Ay H, Kırca O, Ozdogan M. Aloe vera and cancer. Turk J Oncol 2016;31(2):68-72

Nayir E, Keskin O. Do We Initiate Chemotherapy at an Early Stage of Hormone-Sensitive Metastatic Prostate Cancer? Turk J Oncol 2016;31(4)

Nayır E, Sezgin O, Altıntaş E, Üçbilek E, Pratisyen hekimlerin hepatit B ve hepatit C hakkındaki bilgi düzeyleri. Akademik Gastroenteroloji Dergisi 2012;11(2): 58-62

Altintas ZM, Altintas E, Sezgin O, Edgunlu TG, Ucbilek E, Nayir E, Barlas IO, Erdal ME. The Effect of Genetic Variations of Methylene Tetrahydropholate Reductase Gene Polymorphisms on Ribavirin-Induced Anemia in Hepatitis C Patients. J Liver: Dis Transplant 2013;2:1

Altintas E, Altintas ZM, Sezgin O, Ucbilek E, Nayir E, Erdal ME, Polat A, Orekeci G. Polymorphisms in methylenetetrahydrofolate reductase gene: Their impact on liver steatosis and fibrosis of chronic hepatitis c patients. Open Journal of Gastroenterology 2014;4:73-80

Nayir E, Koyuncu MB, Erdogdu S, Ata A, Yılmaz IA, Arican A. Stiff Person Syndrome in a patient with pancreatic adenocarcinoma: An unusual paraneoplastic syndrome. J hum rhythm 2015;1(3):123-126

Nayir E, Arican A. Kanser ve insulin direnci, antidiyabetikler ve non-steroidal anti-inflamatuvar ilaçların kanserde etkileri ve kullanımı. Türkiye Klinikleri J Pharmacol-Special Topics 2015;3(3):36-43

Nayir E. A Rarely Seen Hepatic Tumor: Epithelioid hemangioendothelioma. Ulutas Med J. 2016;2(1):59-62

Nayir E. Pathogenesis of bone metastasis. Journal of Oncological Science 2016;1:13-16

Tabakan F, Nayir E, Arican A. Clinical and pathological evaluation of histopathological subtypes in patients with non-Hodgkin’s lymphoma Eur Res J 2016;2(1):52-61

Unlu A, Kirca O, Ozdogan M, Nayir E. High – dose vitamin C and cancer. Journal of Oncological Science 2016;1:10-12

Nayir E, Köşeci T, Arican A. Bilateral meme kanseri ve mide metastazı: Olgu sunumu. Acta Oncol Tur. 2016;49(3): 232-234

Nayir E, Karacabey B, Kirca O, Ozdogan M. Electronic cigarette (e-cigarette) Journal of Oncological Science 2016;2:16-20

Nayir E, Ata A, Erdogdu S, Salman T, Sungur MA, Abali H, Arican A. A snapshot of residents in medical oncology in Turkey: A Nationwide survey on profile and key problems. Journal of Oncological Science 2016;2:21-24

Kacan T, Nayir E, Altun A, Kilickap S, Babacan NA, Ataseven H, Kaya T. Antitumor activity of sorafenib on colorectal cancer. Journal of Oncological Science 2016;2: 53-57

Nayir E, Ermis E. Chemoradiation of pancreatic carcinoma. Journal of Oncological Science 2016;2: 43-47

Karaytug MO, Gurbuz M, Nayir E, Tamam L. Cancer and psychosocial support. J hum rhythm 2016;2(3):103-108

Bilir C, Yıldız İ, Bilici A, Ucar M, Berk V, Yıldız Y, Yazıcı O, İmamoğlu Gİ, Karadurmuş N, Pilancı KN, Arpacı E, Tanrıverdi Ö, Karcı E, Temiz S, Nayır E, Oktay E, Dal P, Petekkaya İ, Yağmurkaya O, Varım C. Alteration of thyroid functions in patients with renal cell carcinoma treated with tyrosine kinase inhibitors; Turkish population study. J hum rhythm 2016;2(4):144-148

Nayır E, Cor S, Altintas ZM, Buyukafsar K, Tiftik RN, Ata A, Arican A. Comparative investigation of antitumoral effectiveness of Rho-kinase inhibitor Y-27632, pravastatin and atorvastatin in anaplastic thyroid cancer cell culture. Journal of Oncological Sciences 3(2017):62-65

Petekkaya E, Petekkaya I, Nayır E, Altındag K. Is there an association between CRP levels and tumor size in breast cancer patients? Journal of Oncological Sciences 4(2018): 106-107